Search | Clinical Trials Finder

Conditions: Cardiac Amyloidosis, AL Amyloidosis, ATTR Amyloidosis
Interventions: [18F]florbetaben; Drug
Lead sponsor: Lantheus Germany GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Kansas City, Kansas • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Familial Amyloid Polyneuropathy, Familial Amyloidosis
Interventions: diflunisal, placebo; Drug · Other
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 3
States / cities: Boston, Massachusetts • Rochester, Minnesota • New York, New York

Conditions: Amyloidosis, Paraproteinemias, Cardiomyopathies
Interventions: Amyloidosis, Cardiac Amyloidosis; Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Lumbar Spinal Stenosis, Cardiac Amyloidosis, ATTR Amyloidosis Wild Type, ATTR Gene Mutation, ATTRV122I Amyloidosis, Cardiomyopathy, Hypertrophic
Interventions: Tc99-PYP or Tc99-HDMP Scan; Diagnostic Test
Lead sponsor: Columbia University; Other
Eligibility: 50 Years and older
Enrollment: 1,663 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Beverly Hills, California • Boston, Massachusetts • Rochester, Minnesota + 2 more

Conditions: Transthyretin Amyloidosis
Interventions: I 124-Evuzamitide; Drug
Lead sponsor: Columbia University; Other
Eligibility: 50 Years to 105 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Amyloid, Cardiac Amyloidosis, Amyloidosis Cardiac, Systemic Amyloidosis, AL Amyloidosis, Infiltrative Cardiomyopathy, Amyloid, ATTR Amyloidosis Wild Type
Interventions: Chest Wall Fat Tissue Collection; Procedure
Lead sponsor: Midwest Heart & Vascular Specialists; Other
Eligibility: 40 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cardiac Amyloidosis, Heart Diseases, TTR Cardiac Amyloidosis
Interventions: Beta blocker; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 65 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiac Amyloidosis
Interventions: EchoNet-LVH screening for cardiac amyloidosis; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cardiac Amyloidosis
Interventions: [64Cu]FBP8 PET/MR; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hereditary Transthyretin-mediated (ATTRv) Amyloidosis, Polyneuropathy
Interventions: Patisiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 27
States / cities: Los Angeles, California • San Diego, California • Aurora, Colorado + 22 more

Conditions: Cardiac Amyloidosis
Interventions: F-18 florbetapir PET; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amyloidosis; Heart (Manifestation), Senile Cardiac Amyloidosis
Interventions: Tauroursodeoxycholic Acid and Doxycycline; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Interventions: Not listed
Lead sponsor: xCures; Industry
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Altos, California

Conditions: Cardiomyopathy, Ischemic Heart Disease, Cardiac Amyloidosis
Interventions: Transthoracic Echocardiography (TTE); Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10,040,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Transthyretin Cardiac Amyloidosis
Interventions: Tafamidis 61 MG; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Beverly Hills, California • New York, New York • Cleveland, Ohio + 1 more

Conditions: Non-ischemic Cardiomyopathy, Cardiomyopathies, Hypertrophic Cardiomyopathy, Right Ventricular Arrhythmogenic Cardiomyopathy, Cardiac Amyloidosis, Anderson Fabry Disease, Sarcoidosis, Cancer Therapy-related Cardiac Dysfunction, Ventricular Arrythmia, Heart Failure
Interventions: Not listed
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Cardiac Amyloidosis
Interventions: • Cardiac Rehabilitation; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Amyloidosis Transthyretin, Athlete Heart
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Timeline: 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Transthyretin Amyloidosis
Interventions: Computer algorithm for ATTR; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cardiac Amyloidosis
Interventions: [68Ga]CBP8 PET/MRI; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related, Familial Transthyretin Cardiac Amyloidosis
Interventions: Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 41
States / cities: Bakersfield, California • Beverly Hills, California • La Mesa, California + 30 more

Conditions: Lumbar Spinal Stenosis, Carpal Tunnel Syndrome (CTS), Cardiac Amyloidosis
Interventions: 124I-evuzamitide; Drug
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Polyneuropathies, Wild Type ATTR Amyloidosis, Wild-Type Transthyretin-Related (ATTR)Amyloidosis, Wild-Type Transthyretin Cardiac Amyloidosis, Transthyretin Amyloidosis
Interventions: patisiran; Drug
Lead sponsor: Austin Neuromuscular Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions: AI Toolkit for ATTR-CM Diagnosis; Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 50 Years to 95 Years
Enrollment: 1,500,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: San Francisco, California • New Haven, Connecticut • Detroit, Michigan + 8 more

Search by objective public record fields.

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

The Effect of Diflunisal on Familial Amyloidosis

Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR

Amyloidosis Incidence in High-Risk Cardiac Device Patients

N-of-1 for Beta-Blockers in Cardiac Amyloidosis

Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)

[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy

A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation

Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography

Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

A Study Of Deep Learning For Echo Analysis, Tracking, And Evaluation

Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation

Cardiovascular Multimodality Imaging Study

CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study

Exercise Effect on Transthyretin Stability

Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records

Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome

Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy

An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.